Gain-of-function p53 mutations enhance alteration of the T-cell receptor following X-irradiation, independently of the cell cycle and cell survival

Cancer Research

Volumn 56, Issue 17, 1996, Pages 3862-3865

  Iwamoto, Keisuke S ^a   Mizuno, Terumi ^a   Ito, Takashi ^a   Tsuyama, Naohiro ^a   Kyoizumi, Seishi ^a   Seyama, Toshio ^a  

^a RADIATION EFFECTS RESEARCH FOUNDATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; T LYMPHOCYTE RECEPTOR;

APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MISSENSE MUTATION; MUTATOR GENE; PRIORITY JOURNAL; RADIOSENSITIVITY; X IRRADIATION;

ANTIGENS, CD3; CELL CYCLE; CELL SURVIVAL; DRUG STABILITY; GENES, P53; HUMANS; LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED; LYMPHOCYTES; MUTATION; PHENOTYPE; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029837307     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Harris, C. C. Chemical and physical carcinogenesis: advances and perspectives for the 1990s Cancer Res., 51 (Suppl.): 5023s-5044s, 1991.
2. Greenblatt, M. S., Bennett, W P., Hollstein, M , and Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878, 1994.
3. Kuerbitz, S J , Plunkett, B S., Walsh, W. V , and Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad. Sci. USA, 89: 7491-7495, 1995
4. Zhen, W., Denault, C. M., Loviscek, K., Walter, S , Geng, L., and Vaughan, A T. M. The relative radiosensitivity of TK6 and WI-L2-NS lymphoblastoid cells derived from a common source is primarily determined by their p53 mutational status. Mutat. Res , 346: 83-92, 1995.
5. Lowe, S. W., Schmitt, E. M , Smith, S W., Osborne, B. A., and Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes Nature (Lond.), 362: 847-852, 1993.
6. Finlay, C. A., Hinds, P. W., and Levine, A. J The p53 proto-oncogene can act as a suppressor of transformation. Cell, 57: 1083-1093, 1989.
7. Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., and Levine, A. J. Gain of function mutations in p53. Nat. Genet., 4: 42-46, 1993.
8. Hann, B. C., and Lane, D. P. The dominating effect of mutant p53. Nat. Genet., 9: 221-222, 1995
9. Forrester, K , Lupold, S. E., Ott, V. L., Chay, C. H., Band, V., Wang, X. W., and Harris, C. C Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent Oncogene, 10: 2103-2111, 1995
10. Hsiao, M., Low, J , Dorn, E., Ku, D., Pattengale, P., Yeargin, J., and Haas, M. Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am. J. Pathol , 145: 702-714, 1994
11. Reid, R. L , Lindholm, P. F., Mireskandari, A., Dittmer, J., and Brady, J. N. Stabilization of wild-type p53 in human T-lymphocytes transformed by HTLV-I. Oncogene, 8: 3029-3036, 1993.
12. + cells J Exp. Med., 171: 1981-1999, 1990.
13. Furth, E. E , Thilly, W. G , Penman, B. W., Liber, H. L., and Rand, W M. Quantitative assay for mutation m diploid human lymphoblasts using microtiter plates. Anal. Biochem., 110: 1-8, 1981.
14. Meuer, S. C., Fitzgerald, K. A., Hussey, R. E., Hodgdon, J. C , Schlossman, S. F , and Reinherz, E. L. Clonotypic structures involved in antigen-specific human T cell function: relationship to the T3 molecular complex. J. Exp. Med , 157: 705-719, 1983.
15. Iwamoto, K. S., Hirai, Y., Umeki, S , Kusunoki, Y., Kyoizumi, S , Kodama, T., Ohama, K , Nakamura, N , and Akiyama, M. A positive correlation between T-cell-receptor mutant frequencies and dicentric chromosome frequencies in lymphocytes from radiotherapy patients J. Radiat. Res , 35: 92-103, 1994.
16. Hirota, H., Kubota, M., Adachi, S., Okuda, A , Lin, Y. W., Bessho, R., Wakazono, Y , Matsubara, K , Kuwakado, K., Akiyama, Y , and Tsutsui, T. Somatic mutations at T-cell antigen receptor and glycophorin A loci in pediatric leukemia patients following chemotherapy: comparison with HPRT locus mutation. Mutat Res , 315: 95-103, 1994.
17. Evans, H H , Ricanati, M., Horng, M-F , Jiang, Q., Mencl, J., and Olive, P. DNA double-strand break rejoining deficiency in TK6 and other human B-lymphoblast cell lines. Radiat Res., 134: 307-315, 1993.
18. Lane, D. P., and Benchimol, S. p53: oncogene or anti-oncogene? Genes Dev., 4 1-8, 1990.
19. Wolf, D , Harris, N., and Rotter, V. Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene. Cell, 38: 119-126, 1984.
20. Eliyahu, D., Michalovitz, D , and Oren, M. Overproduction of p53 antigen makes established cells highly tumorigenic. Nature (Lond.), 316: 158-160, 1985.
21. Pohl, J., Goldfinger, N., Radler-Pohl, A., Rotter, V , and Schirrmacher, V. p53 increases experimental metastatic capacity of murine carcinoma cells Mol. Cell. Biol , 8: 2078-2081, 1988.
22. Lee, J. M., Abrahamson, J. L. A., Kandel, R., Donehower, L. A., and Bernstein, A. Susceptibility to radiation-carcinogenesis and accumulation of chromosomal breakage in p53 deficient mice Oncogene, 9: 3731-3736, 1994
23. Suzushima, H., Hattori, T , Asou, N , Wang, J., Nishikawa, K., Okubo, T., Anderson, P., and Takatsuki, K Discordant gene and surface expression of the T-cell receptor/ CD3 complex in adult T-cell leukemia cells Cancer Res., 51: 6084-6088, 1991.
24. Nichols, J., and Nimer, S. D Transcription factors, translocations, and leukemias. Blood, 80: 2953-2963, 1992
25. Prokocimer, M., and Rotter, V. Structure and function of p53 in normal cells and their aberrations in cancer cells projection on the hematologic cell lineages. Blood, 84: 2391-2411, 1994
26. Hsiao, M H , Yu, A. L., Yeargin, J , Ku, D., and Haas, M. Nonhereditary p53 mutations in T-cell acute lymphoblastic leukemia are associated with relapse phase Blood, 83: 2922-2930, 1994